BLFS Biolife Solutions Inc

Price (delayed)

$15.72

Market cap

$666.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.35

Enterprise value

$633.19M

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage ...

Highlights
The company's revenue has surged by 163% YoY and by 16% QoQ
The equity has soared by 129% YoY
The debt has surged by 132% year-on-year but it has declined by 3.3% since the previous quarter
BLFS's net income has dropped by 78% since the previous quarter but it is up by 34% year-on-year
BLFS's gross margin is down by 48% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of BLFS
Market
Shares outstanding
42.41M
Market cap
$666.68M
Enterprise value
$633.19M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
4.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.57
Earnings
Revenue
$138.53M
EBIT
-$33.72M
EBITDA
-$15.88M
Free cash flow
-$26.93M
Per share
EPS
-$0.35
Free cash flow per share
-$0.65
Book value per share
$11.37
Revenue per share
$3.32
TBVPS
$4.08
Balance sheet
Total assets
$544.01M
Total liabilities
$65.49M
Debt
$25.99M
Equity
$478.52M
Working capital
$83.66M
Liquidity
Debt to equity
0.05
Current ratio
3.39
Quick ratio
2.39
Net debt/EBITDA
2.11
Margins
EBITDA margin
-11.5%
Gross margin
28.5%
Net margin
-9.8%
Operating margin
-29.3%
Efficiency
Return on assets
-2.5%
Return on equity
-2.9%
Return on invested capital
-34.5%
Return on capital employed
-6.6%
Return on sales
-24.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLFS stock price

How has the Biolife Solutions stock price performed over time
Intraday
0%
1 week
14%
1 month
27.6%
1 year
-64.59%
YTD
-57.82%
QTD
-30.84%

Financial performance

How have Biolife Solutions's revenue and profit performed over time
Revenue
$138.53M
Gross profit
$39.53M
Operating income
-$40.56M
Net income
-$13.58M
Gross margin
28.5%
Net margin
-9.8%
The operating margin has plunged by 166% YoY and by 12% from the previous quarter
The company's revenue has surged by 163% YoY and by 16% QoQ
BLFS's net income has dropped by 78% since the previous quarter but it is up by 34% year-on-year
The net margin has surged by 75% year-on-year but it has dropped by 53% since the previous quarter

Growth

What is Biolife Solutions's growth rate over time

Valuation

What is Biolife Solutions stock price valuation
P/E
N/A
P/B
1.38
P/S
4.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.57
The EPS has dropped by 75% since the previous quarter but it has surged by 59% year-on-year
The equity has soared by 129% YoY
BLFS's price to book (P/B) is 78% lower than its 5-year quarterly average of 6.2 and 57% lower than its last 4 quarters average of 3.2
The company's revenue has surged by 163% YoY and by 16% QoQ
The P/S is 68% lower than the last 4 quarters average of 14.9 and 64% lower than the 5-year quarterly average of 13.0

Efficiency

How efficient is Biolife Solutions business performance
Biolife Solutions's return on assets has surged by 76% YoY but it has shrunk by 56% QoQ
The ROE has soared by 75% YoY but it has plunged by 53% from the previous quarter
The return on sales has grown by 46% year-on-year but it has declined by 6% since the previous quarter
The ROIC has grown by 43% YoY but it has contracted by 10% from the previous quarter

Dividends

What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLFS.

Financial health

How did Biolife Solutions financials performed over time
The total assets has soared by 127% YoY
The total liabilities has soared by 110% YoY but it has decreased by 11% from the previous quarter
The debt is 95% smaller than the equity
The debt has surged by 132% year-on-year but it has declined by 3.3% since the previous quarter
The equity has soared by 129% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.